ABBVIE INC (4AB.DE) Stock Fundamental Analysis
Europe - FRA:4AB - US00287Y1091 - Common Stock
190.4 EUR
+1.8 (+0.95%)
Overall 4AB gets a fundamental rating of 5 out of 10. We evaluated 4AB against 76 industry peers in the Biotechnology industry. 4AB scores excellent on profitability, but there are concerns on its financial health. 4AB has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
4AB had positive earnings in the past year.
In the past year 4AB had a positive cash flow from operations.
Each year in the past 5 years 4AB has been profitable.
In the past 5 years 4AB always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 2.71%, 4AB belongs to the best of the industry, outperforming 80.26% of the companies in the same industry.
4AB has a Return On Invested Capital of 13.81%. This is amongst the best in the industry. 4AB outperforms 90.79% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 4AB is in line with the industry average of 12.82%.
The 3 year average ROIC (13.67%) for 4AB is below the current ROIC(13.81%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.71% | ||
| ROE | N/A | ||
| ROIC | 13.81% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
1.3 Margins
Looking at the Profit Margin, with a value of 6.38%, 4AB belongs to the top of the industry, outperforming 84.21% of the companies in the same industry.
4AB's Profit Margin has declined in the last couple of years.
The Operating Margin of 4AB (31.27%) is better than 90.79% of its industry peers.
4AB's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 70.93%, 4AB is doing good in the industry, outperforming 65.79% of the companies in the same industry.
In the last couple of years the Gross Margin of 4AB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.27% | ||
| PM (TTM) | 6.38% | ||
| GM | 70.93% |
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 4AB is still creating some value.
4AB has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, 4AB has more shares outstanding
4AB has a worse debt/assets ratio than last year.
2.2 Solvency
4AB has an Altman-Z score of 2.33. This is not the best score and indicates that 4AB is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of 4AB (2.33) is better than 69.74% of its industry peers.
The Debt to FCF ratio of 4AB is 3.86, which is a good value as it means it would take 4AB, 3.86 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 3.86, 4AB belongs to the best of the industry, outperforming 82.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.86 | ||
| Altman-Z | 2.33 |
ROIC/WACC1.67
WACC8.25%
2.3 Liquidity
A Current Ratio of 0.74 indicates that 4AB may have some problems paying its short term obligations.
4AB's Current ratio of 0.74 is on the low side compared to the rest of the industry. 4AB is outperformed by 77.63% of its industry peers.
A Quick Ratio of 0.61 indicates that 4AB may have some problems paying its short term obligations.
4AB has a Quick ratio of 0.61. This is in the lower half of the industry: 4AB underperforms 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.61 |
3. Growth
3.1 Past
4AB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.09%.
4AB shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.51% yearly.
4AB shows a small growth in Revenue. In the last year, the Revenue has grown by 3.71%.
Measured over the past years, 4AB shows a quite strong growth in Revenue. The Revenue has been growing by 11.11% on average per year.
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
Revenue 1Y (TTM)3.71%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
3.2 Future
Based on estimates for the next years, 4AB will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.59% on average per year.
Based on estimates for the next years, 4AB will show a small growth in Revenue. The Revenue will grow by 7.22% on average per year.
EPS Next Y6.19%
EPS Next 2Y19.88%
EPS Next 3Y16.85%
EPS Next 5Y13.59%
Revenue Next Year8.23%
Revenue Next 2Y8.64%
Revenue Next 3Y8.27%
Revenue Next 5Y7.22%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 23.25, 4AB is valued on the expensive side.
Based on the Price/Earnings ratio, 4AB is valued cheaper than 82.89% of the companies in the same industry.
When comparing the Price/Earnings ratio of 4AB to the average of the S&P500 Index (25.67), we can say 4AB is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 15.10, the valuation of 4AB can be described as correct.
4AB's Price/Forward Earnings ratio is rather cheap when compared to the industry. 4AB is cheaper than 89.47% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of 4AB to the average of the S&P500 Index (31.86), we can say 4AB is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.25 | ||
| Fwd PE | 15.1 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 4AB is valued cheaply inside the industry as 80.26% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, 4AB is valued cheaply inside the industry as 86.84% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.27 | ||
| EV/EBITDA | 16.7 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 4AB does not grow enough to justify the current Price/Earnings ratio.
4AB has a very decent profitability rating, which may justify a higher PE ratio.
4AB's earnings are expected to grow with 16.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.76
PEG (5Y)9.26
EPS Next 2Y19.88%
EPS Next 3Y16.85%
5. Dividend
5.1 Amount
4AB has a Yearly Dividend Yield of 2.87%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 11.67, 4AB pays a better dividend. On top of this 4AB pays more dividend than 96.05% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.40, 4AB has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.87% |
5.2 History
The dividend of 4AB is nicely growing with an annual growth rate of 7.72%!
Dividend Growth(5Y)7.72%
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
4AB pays out 304.54% of its income as dividend. This is not a sustainable payout ratio.
4AB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP304.54%
EPS Next 2Y19.88%
EPS Next 3Y16.85%
FRA:4AB (11/7/2025, 2:57:15 PM)
190.4
+1.8 (+0.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners74.42%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap336.35B
Revenue(TTM)56.33B
Net Income(TTM)3.72B
Analysts79.46
Price Target208.81 (9.67%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.87% |
Yearly Dividend5.4
Dividend Growth(5Y)7.72%
DP304.54%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.04%
Min EPS beat(2)0.95%
Max EPS beat(2)1.14%
EPS beat(4)4
Avg EPS beat(4)0.75%
Min EPS beat(4)0.02%
Max EPS beat(4)1.14%
EPS beat(8)7
Avg EPS beat(8)0.76%
EPS beat(12)9
Avg EPS beat(12)0.46%
EPS beat(16)11
Avg EPS beat(16)0.4%
Revenue beat(2)2
Avg Revenue beat(2)0.93%
Min Revenue beat(2)0.63%
Max Revenue beat(2)1.23%
Revenue beat(4)2
Avg Revenue beat(4)0.24%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.36%
Revenue beat(12)5
Avg Revenue beat(12)-0.32%
Revenue beat(16)5
Avg Revenue beat(16)-0.81%
PT rev (1m)9.9%
PT rev (3m)12.94%
EPS NQ rev (1m)-45.37%
EPS NQ rev (3m)-45.01%
EPS NY rev (1m)-12.38%
EPS NY rev (3m)-13.25%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)0.95%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)1.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.25 | ||
| Fwd PE | 15.1 | ||
| P/S | 6.65 | ||
| P/FCF | 21.27 | ||
| P/OCF | 20.12 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.7 |
EPS(TTM)8.19
EY4.3%
EPS(NY)12.61
Fwd EY6.62%
FCF(TTM)8.95
FCFY4.7%
OCF(TTM)9.46
OCFY4.97%
SpS28.63
BVpS-0.09
TBVpS-45.57
PEG (NY)3.76
PEG (5Y)9.26
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.71% | ||
| ROE | N/A | ||
| ROCE | 18.72% | ||
| ROIC | 13.81% | ||
| ROICexc | 14.74% | ||
| ROICexgc | 370.81% | ||
| OM | 31.27% | ||
| PM (TTM) | 6.38% | ||
| GM | 70.93% | ||
| FCFM | 31.27% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score6
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.86 | ||
| Debt/EBITDA | 2.58 | ||
| Cap/Depr | 12.62% | ||
| Cap/Sales | 1.79% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 72.74% | ||
| Profit Quality | 489.9% | ||
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.61 | ||
| Altman-Z | 2.33 |
F-Score6
WACC8.25%
ROIC/WACC1.67
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
EPS Next Y6.19%
EPS Next 2Y19.88%
EPS Next 3Y16.85%
EPS Next 5Y13.59%
Revenue 1Y (TTM)3.71%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
Revenue Next Year8.23%
Revenue Next 2Y8.64%
Revenue Next 3Y8.27%
Revenue Next 5Y7.22%
EBIT growth 1Y13.81%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year20.95%
EBIT Next 3Y15.22%
EBIT Next 5Y11.27%
FCF growth 1Y-26.45%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-24.5%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%
ABBVIE INC / 4AB.DE FAQ
What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.
What is the valuation status of ABBVIE INC (4AB.DE) stock?
ChartMill assigns a valuation rating of 6 / 10 to ABBVIE INC (4AB.DE). This can be considered as Fairly Valued.
How profitable is ABBVIE INC (4AB.DE) stock?
ABBVIE INC (4AB.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of ABBVIE INC (4AB.DE) stock?
The Price/Earnings (PE) ratio for ABBVIE INC (4AB.DE) is 23.25 and the Price/Book (PB) ratio is -2119.76.
Can you provide the expected EPS growth for 4AB stock?
The Earnings per Share (EPS) of ABBVIE INC (4AB.DE) is expected to grow by 6.19% in the next year.